Prelude Therapeutics (PRLD)
NASDAQ:PRLD
Want to see PRLD full AI Analyst Report?
Top Page
Prelude Therapeutics
(NASDAQ:PRLD)
Select Model
Select Model
Rating:51Neutral
Price Target:
$4.50
▲(83.67% Upside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (large ongoing losses, negative free cash flow, and shrinking equity base) despite improving revenue and moderating cash burn. Technicals are supportive with the stock trading above major moving averages and positive MACD, but valuation is constrained by a negative P/E and no indicated dividend yield.
Positive Factors
Regulatory clearance and Phase 1 initiation
FDA IND clearance and the start of a Phase 1 trial transition Prelude from discovery to clinical-stage execution. This materially de-risks that program, enables generation of human proof-of-concept data, and creates durable near-to-medium-term value inflection points for partnerships and licensing.
Negative Factors
Sustained net losses and negative cash generation
Large, persistent operating losses and negative operating/free cash flow mean ongoing capital consumption. Over the medium term this forces repeated external funding, constrains reinvestment optionality, and raises execution risk if financing conditions tighten before product revenues materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clearance and Phase 1 initiation
FDA IND clearance and the start of a Phase 1 trial transition Prelude from discovery to clinical-stage execution. This materially de-risks that program, enables generation of human proof-of-concept data, and creates durable near-to-medium-term value inflection points for partnerships and licensing.
Read all positive factors
Prelude Therapeutics (PRLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$282.25M
Dividend YieldN/A
Average Volume (3M)256.05K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth138.86%
EPS Growth42.14%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding48,274,113
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue14.22
Enterprise Value/Gross Profit14.56
Enterprise Value/Ebitda-2.88
Forecast
1Y Price Target
$7.67Price Target Upside212.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$27.30M
Prelude Therapeutics Business Overview & Revenue Model
Company Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in sel...
How the Company Makes Money
Prelude Therapeutics does not appear to generate material recurring revenue from product sales because it is a clinical-stage company without marketed therapies. Its potential and historical sources of revenue are primarily (1) collaboration and l...
Prelude Therapeutics Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.Positive Updates
Strategic Decisions and Financial Position
Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
Negative Updates
Potential Competition
The presence of competitors in both JAK2 and KAT6A spaces, including established players like Pfizer, poses a challenge in differentiating Prelude's offerings.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Decisions and Financial Position
Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
Read all positive updates
Company Guidance
During the Prelude Therapeutics Investor Conference Call, the company provided guidance on its strategic focus and future clinical development activities. Prelude is set to advance two key development candidates into clinical trials by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. The JAK2V617F inhibitor targets a mutation present in over 95% of polycythemia vera patients and 50-60% of patients with myelofibrosis and essential thrombocythemia, representing a market of over 200,000 MPN patients in the U.S. alone. The KAT6A program aims to address resistance in ER-positive breast cancer, with preclinical data suggesting a differentiated safety and efficacy profile over existing treatments. Prelude announced a significant $910 million deal with Incyte, including an upfront payment of $60 million, providing a financial runway into 2027, and plans to file an Investigational New Drug (IND) application for the JAK2 program in early 2026.Prelude Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.72M | 12.14M | 7.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.33M | 10.43M | 7.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -82.47M | -102.86M | -137.94M | -131.11M | -122.22M | -112.82M |
| Net Income | -77.80M | -99.50M | -127.17M | -121.83M | -115.44M | -111.69M |
Balance Sheet | ||||||
| Total Assets | 119.64M | 141.31M | 175.51M | 277.67M | 220.50M | 305.10M |
| Cash, Cash Equivalents and Short-Term Investments | 81.55M | 103.21M | 133.61M | 232.94M | 201.73M | 291.23M |
| Total Debt | 17.72M | 17.79M | 18.02M | 16.89M | 1.83M | 1.74M |
| Total Liabilities | 59.46M | 72.68M | 44.06M | 40.58M | 25.06M | 19.20M |
| Stockholders Equity | 60.18M | 68.64M | 131.46M | 237.09M | 195.44M | 285.90M |
Cash Flow | ||||||
| Free Cash Flow | -43.78M | -56.37M | -103.65M | -110.58M | -86.75M | -85.85M |
| Operating Cash Flow | -43.76M | -56.30M | -102.89M | -107.06M | -83.73M | -83.53M |
| Investing Cash Flow | -228.00K | 53.46M | 90.19M | -34.65M | 81.69M | -263.80M |
| Financing Cash Flow | 24.66M | 24.82M | -120.00K | 136.40M | 815.00K | 164.90M |
Prelude Therapeutics Technical Analysis
Neutral
2.45
Price Trends
4.07
Positive
3.24
Positive
2.31
Positive
Market Momentum
0.12
Positive
47.73
Neutral
22.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Neutral. The current price of 2.45 is below the 20-day moving average (MA) of 4.64, below the 50-day MA of 4.07, and above the 200-day MA of 2.31, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 22.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRLD.
Prelude Therapeutics Risk Analysis
Prelude Therapeutics disclosed 77 risk factors in its most recent earnings report. Prelude Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prelude Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $282.25M | -6.79 | -118.24% | ― | 138.86% | 42.14% | |
47 Neutral | $74.64M | -3.65 | -201.43% | ― | ― | 33.86% | |
42 Neutral | $36.03M | -0.97 | -198.48% | ― | -0.46% | 96.28% | |
42 Neutral | $68.80M | -0.92 | -68.98% | ― | ― | -26.14% |
* Healthcare Sector Average
PRLD
Prelude Therapeutics
4.34
3.36
342.86%
PSTV
Plus Therapeutics
5.84
-2.10
-26.42%
PMVP
PMV Pharmaceuticals
1.25
0.32
34.41%
GANX
Gain Therapeutics
1.62
-0.29
-15.18%
IMMX
Immix Biopharma
8.99
6.88
326.07%
Prelude Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
Positive
May 12, 2026
Prelude Therapeutics reported first-quarter 2026 results on May 12, 2026, highlighting the start of a Phase 1 trial for PRT12396, its mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, following U.S. regulatory clearance...
Business Operations and StrategyPrivate Placements and Financing
Prelude Therapeutics Prices Public Offering to Extend Runway
Positive
Apr 21, 2026
On April 20, 2026, Prelude Therapeutics announced the pricing of an underwritten public offering of 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants for up to 2,252,252 additional shares at $4.4399 each. The transaction...
Business Operations and StrategyProduct-Related Announcements
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
Positive
Apr 20, 2026
On April 20, 2026, Prelude Therapeutics announced new preclinical data for its lead candidate PRT13722, a first-in-class, orally bioavailable and highly selective KAT6A degrader being developed for HR-positive/HER2-negative breast cancer. The data...
Business Operations and StrategyExecutive/Board Changes
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
Positive
Apr 15, 2026
On April 15, 2026, Prelude Therapeutics announced that veteran oncologist Charles Morris, M.D., will join the company as Executive Vice President and Chief Medical Officer effective April 20, 2026, bringing more than 30 years of oncology drug deve...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Prelude Therapeutics Establishes New ATM Equity Offering Facility
Positive
Mar 12, 2026
Prelude Therapeutics said that, under a previously established Open Market Sale Agreement with Jefferies LLC, it has the ability to issue and sell up to $75 million of its common stock. On March 12, 2026, the company filed a prospectus supplement ...
Business Operations and StrategyFinancial Disclosures
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
Positive
Mar 10, 2026
Prelude Therapeutics reported full-year 2025 financial results on March 10, 2026, and outlined a 2026 program roadmap centered on its JAK2V617F and KAT6A programs. The company ended 2025 with $106.4 million in cash and equivalents, expects its cas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.